Advanced Search

Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2005 September;57(3) > Minerva Urologica e Nefrologica 2005 September;57(3):175-97

ISSUES AND ARTICLES   MOST READ   eTOC

CURRENT ISSUEMINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology

Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,536

Frequency: Bi-Monthly

ISSN 0393-2249

Online ISSN 1827-1758

 

Minerva Urologica e Nefrologica 2005 September;57(3):175-97

    REVIEWS

Hepatitis C virus in chronic dialysis patients

Natov S. N. 1, Pereira B. J. G. 2,3

1 Northeast Specialty Hospital Braintree, Natick, Stoughton, Waltham, MA, USA
2 Tufts University School of Medicine Boston, MA, USA
3 New England Health Care Foundation

Since the cloning of hepatitis C virus (HCV), numerous serologic and virologic tests for detecting HCV infection have been developed and implemented in clinical practice. As a result, significant advances have been made in the study of HCV infection in patients with end-stage kidney disease. Patients on hemodialysis have a higher incidence and prevalence of HCV infection than the general population. In addition, HCV infection affects adversely survival among patients with end-stage kidney disease. Risk factors for HCV infection in dialysis patients include number of blood transfusions, duration of hemodialysis, mode of dialysis, prevalence of HCV infection in the dialysis unit, previous organ transplantation, intravenous drug use, male gender, older age and nosocomial transmission of HCV in hemodialysis units that can occur due to breakdown in standard infection control practices, physical proximity to an infected patient, cross-infection through dialysis machines, disrupted integrity of dialyzer membrane or dialyzer reprocessing. Suggested strategies to control HCV transmission in hemodialysis units include strict adherence to universal precautions, careful attention to hygiene, sterilization of dialysis machines and routine serologic testing and surveillance for HCV infection. Antiviral therapy with interferon alfa is recommended for selected categories of HCV-infected hemodialysis patients and kidney transplant candidates.

language: English


FULL TEXT  REPRINTS

top of page